ABSTRACT
Objective This study evaluated patterns of utilization, complications, and costs of endomyocardial biopsies (EMB) in heart transplant patients.
Methods The IBM® Treatment Pathways® tool was used to analyze claims data selected from the IBM®’s MarketScan® de-identified, HIPAA-compliant dataset. Differences in EMB paid amounts and utilization patterns were assessed for commercial payers and Medicare for years 2016 to 2019. Type, frequency, and overall cost of complications of the EMB procedure in these patients were also evaluated.
Results A total of 8,170 records (6,385 commercial payers and 1,785 Medicare) of heart transplant patients with evidence of EMB procedures performed between 2016 and 2019 were identified in the database. In 2019, the median paid amount for an outpatient EMB in a heart transplant patient was US $7,918 (commercial) and US $2,980 (Medicare). Heart transplant patients received between 4.6 and 6.8 (median; Medicare, commercial) EMBs the first year after the transplant. Approximately 25% of EMB procedures were associated with complications. In 2019 the total cost of EMB complications per patient was US $9,049.
Discussion Analysis showed that the paid amount for the EMB procedure increased by almost 25% from 2016 to 2019 for commercial payers. Given the high frequency of complications after the EMB procedure and the associated cost of the complications it is estimated that the median paid amounts are closer to US $10,000 per patient per EMB. Given the number of EMBs provided, the associated risks, and the paid amount trends, non-invasive alternatives to EMB should be considered for the surveillance of heart transplant patients.
Competing Interest Statement
Work supported by CareDx.
Funding Statement
Work supported by CareDx.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest: The author received financial support from CareDx, Inc. for the research, writing and publication of this article.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
